CompletedNot Applicable

ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)

France92 participantsStarted 2021-01-20

Plain-language summary

In this retrospective observational multicenter study the authors tested the hypothesis that the use of IMPELLA™ pump as bridge to bridge, by giving the opportunity of active rehabilitation, should improve patient's outcomes after the implantation of Left Ventricular Assist Device (LVAD).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients supported with IMPELLA™ or ECLS for refractory cardiogenic shock as a bridge to long duration LVAD Exclusion Criteria: * Patient refusing to give access to their medical chart * Guardianship and curactorship * Deprived of liberty * short term mechanical circulatory system weaned before LVAD implantation

What they're measuring

Proportion of patients alive in the surgery ward, not requiring intravenous access and walking (John Hopkins highest level of mobility (JH-HLM) scale = 8 at 30 days after the LVAD implantation

Timeframe: Day 30 after Left Ventricular Assist Device (LVAD) implantation

Trial details

NCT IDNCT04480151

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-04-21

View on ClinicalTrials.gov More Cardiogenic Shock trials